New Vincristine for ALL

Liposomal vincristine received accelerated FDA approval for the treatment of adult patients with Philadelphia chromosome (Ph)-negative ALL (acute lymphocytic leukemia) in second or greater relapse that have progressed after 2 or more lines of antileukemic therapy.  This preparation of vincristine has less neurologic toxicity than traditional vincristine.